Videos
Videos
LATEST VIDEOS
Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML
PRESENTED BY
Presented by Nitin Agarwal and Kristen Floyd from MD Anderson Cancer Center
Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments
PRESENTED BY
Presented by Katja Manninen, MS, MB(ASCP)CM - Field Applications Scientist at Invivoscribe, Inc.
Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL
PRESENTED BY
Presented by Prof. Myungshin Kim and Dr. Roisin McAvera, BSc (Hons), PhD
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02
PRESENTED BY
Presented by Dr. Wayne Yu from Memorial Sloan Kettering Cancer Center
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01
PRESENTED BY
Dr. Artur Kibler from the Institute of Cell Biology (Cancer Research) Medical Faculty, University of Duisburg-Essen
Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML
PRESENTED BY
Presented by Nitin Agarwal and Kristen Floyd from MD Anderson Cancer Center
Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments
PRESENTED BY
Presented by Katja Manninen, MS, MB(ASCP)CM - Field Applications Scientist at Invivoscribe, Inc.
Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL
PRESENTED BY
Presented by Prof. Myungshin Kim and Dr. Roisin McAvera, BSc (Hons), PhD
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02
PRESENTED BY
Presented by Dr. Wayne Yu from Memorial Sloan Kettering Cancer Center
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01
PRESENTED BY
Dr. Artur Kibler from the Institute of Cell Biology (Cancer Research) Medical Faculty, University of Duisburg-Essen
Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments
PRESENTED BY
Dr. Tony Sanchez and Josh Wemmer from Invivoscribe, Inc.
The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML
PRESENTED BY
Dr. Bevan Tandon, Chief Medical Officer of siParadigm Diagnostics Informatics and Dr. Jason Willis, Lead Hematopathologist of LabPMM (a wholly-owned subsidiary of Invivoscribe) at the AMP 2023 Annual Meeting & Expo
MRD Applications and Analysis
PRESENTED BY
Dr. Linda Lee from Royal North Shore Hospital and Dr. Irene Della Starza from Fondazione GIMEMA Franco Mandelli Onlus and Sapienza University, Rome
NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers
PRESENTED BY
Kseniya Petrova-Drus M.D., PhD from Memorial Sloan Kettering Cancer Center
Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring
PRESENTED BY
Joseph Annunziata, M.D. from Kindred Healthcare
We are Invivoscribe – Company Overview
PRESENTED BY
Jeffrey E. Miller, PhD - CSO, CEO, and Founder of Invivoscribe, Inc.
Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience
PRESENTED BY
Rishu Agarwal, MBBS PhD FRCPA and Stephen B. Ma, BBiomedSc BSc(Hone) MD DipMus LMus(dist) - Austin Health
Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing
PRESENTED BY
Sean T. Glenn, PhD - Roswell Park Comprehensive Cancer Center
High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies
PRESENTED BY
Jack Tung, MD, PhD - Stanford University
NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination
PRESENTED BY
Dr. Alejandro Medina Herrera from University Hospital of Salamanca and Dr. Carolina Terragna from IRCCS – University Hospital of Bologna
A Comprehensive Solution for AML Precision Diagnostics
FEATURED PRESENTER
Dr. Ying Huang, Ph.D.
Next-generation sequencing of immunoglobulin genes in lymphoid malignancies
FEATURED PRESENTERS
Dr. Rena Xian, M.D., M.S.
Corporate Overview
Invivoscribe is a technology-driven international company focused on precision diagnostics with best-in-class products and services that optimize patient care and accelerate drug approvals worldwide.
Lab Secrets: Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS)
FEATURED PRESENTERS
Riccardo Bomben, MD and Wouter De Brouwer, MD
Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing
FEATURED PRESENTERS
Dr. Siby Sebastian, PhD, DABMGG, DABCC, NYCOQ
Global Standardization of Flow Cytometry Results with AI Systems
FEATURED PRESENTERS
Meindert Niemeijer, Chief Information Officer / Julian D'Angelo, Bioinformatics Manager
Explore the Benefits, Considerations, and Utility of NGS B- and T-cell Clonality
FEATURED PRESENTERS
Dr. B. Melody Zhang, MD, MS, FCAP, A(ACHI) / Bijal A. Parikh, MD, PhD
Critical Mistakes to Avoid when Developing a Drug/CDx Combination for International Registrations
FEATURED PRESENTERS
Jason Gerhold / Global Director of Regulatory, Quality, and Clinical Affairs Invivoscribe, Inc.
A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System
FEATURED PRESENTERS
Robert Andrews / Director, Flow Cytometry Lab, LabPMM
Assessment of MRD by NGS in Daily Clinical Management of Multiple Myeloma
FEATURED PRESENTERS
Carolina Terragna, PhD
New Frontiers in Hematology: From CLL Tumor Precursor Cells to Tracking Disease Burden in Multiple Myeloma
FEATURED PRESENTERS
Marc Seifert, PD Dr. rer. Nat.
Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies
FEATURED PRESENTERS
Ola Landgren, PhD, MD / Swati Shah, MD
Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology
FEATURED PRESENTER
Dr. Bradley Patay
Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing
FEATURED PRESENTERS
Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD
VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies
FEATURED PRESENTERS
Prof. Dr. Markus Tiemann
VIRTUAL EHA: Clonality analysis with NGS is the new frontier in MRD detection
FEATURED PRESENTERS
Prof. Sara Galimberti
VIRTUAL EHA: Incorporating NGS Methods for Routine Clonality Assessment and Disease Monitoring of Lymphoid Malignancies
FEATURED PRESENTERS
Dr. Maria Arcila
Clinical Utility of NGS in Lymphoid Malignancies
FEATURED PRESENTERS
Yury Monczak, PhD / Bevan Tandon, MD
AMP 2019 Video Series Part 4 of 4
FEATURED PRESENTERS
Rena Ruiyu Xian, M.D., M.S.
AMP 2019 Video Series Part 3 of 4
FEATURED PRESENTERS
Jane Houldsworth PhD
AMP 2019 Video Series Part 2 of 4
FEATURED PRESENTERS
Bevan Tandon M.D.
AMP 2019 Video Series Part 1 of 4
FEATURED PRESENTERS
Bevan Tandon M.D.
Invivoscribe – EHA 2019: Part 3 of 3
FEATURED PRESENTERS
Fiona Quinn
Invivoscribe – EHA 2019: Part 2 of 3
FEATURED PRESENTERS
Marc Seifert
Invivoscribe – EHA 2019: Part 1 of 3
FEATURED PRESENTERS
Marleen Bakkus
Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay
FEATURED PRESENTERS
Dr. Bradley Patay
AMP Global 2019 Video Series Part 4 of 4
FEATURED PRESENTERS
Dr. Rena Xian, M.D., M.S.
AMP Global 2019 Video Series Part 3 of 4
FEATURED PRESENTERS
Dr. Rena Xian, M.D., M.S.
AMP Global 2019 Video Series Part 2 of 4
FEATURED PRESENTERS
Roshanak Bob
AMP Global 2019 Video Series Part 1 of 4
FEATURED PRESENTERS
Bettina Budeus
